New Energy Metals Corp
Change company Symbol lookup
Select an option...
NEMCF New Energy Metals Corp
SLCT Select Bancorp Inc
HPQ HP Inc
GOLD Barrick Gold Corp
DGNR Dragoneer Growth Opportunities Corp
EQMEF Equity Metals Corp
TS Tenaris SA
TRXC Transenterix Inc
TRX Tanzanian Gold Corp
TRVN Trevena Inc
Go


Based in Canada
Company profile

New Energy Metals Corp., formerly Darien Resource Development Corp, is a Canada-based company engaged in the acquisition and exploration of mineral properties. The Company operates mainly in Canada. Darien Resource Development Corp explores for a number of chemical elements, including gold, silver, copper, and zinc deposits, among others.

Price
Delayed
$0.0785
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)

Today's volume of 0 shares is on pace to be much lighter than NEMCF's 10-day average volume of 440 shares.

0

UPDATE: Bristol-Myers, Pfizer stocks rise on blood-thinner patent win

6:28 pm ET August 5, 2020 (MarketWatch)
Print

Bristol-Myers Squibb Co. (BMY) shares rallied in the extended session Wednesday after a federal judge ruled for it and Pfizer Inc. (PFE) in a key patent fight over a blood thinner. Bristol-Myers shares surged 4.4% after hours, following a 0.4% rise to close at $59.69. Pfizer shares advanced 1.5% after hours, following a 0.2% gain to close at $38.45. In a ruling Wednesday, a federal judge said that products made by Sigmapharm Laboratories LLC, Sunshine Lake Pharma Co., and Unichem Laboratories Ltd. infringed patents protecting the blood-thinner Eliquis,, which is generically known as apixaban. Bristol-Myers and Pfizer have a profit-sharing agreement on the drug. "While subject to appeal, at present the generic manufacturers currently involved in the case cannot launch their apixaban products until 2031," said a Bristol-Myers Squibb spokewoman in emailed comments. "Based on settlement agreements reached with other generic manufacturers, we currently expect generic entry could occur after 2026 but before 2031, subject to appeals and future challenges." In 2019, Eliquis was Bristol-Myers's top-selling drug with sales of $2.03 billion, following its acquisition of Celgene in November (http://www.marketwatch.com/story/bristol-myers-squibb-completes-74-billion-acquisition-of-celgene-2019-11-20).

-Wallace Witkowski; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

August 05, 2020 18:28 ET (22:28 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.